nodes	percent_of_prediction	percent_of_DWPC	metapath
Bisacodyl—GPR55—GPCRs, Other—GRM8—lung cancer	0.0259	0.0797	CbGpPWpGaD
Bisacodyl—Haematochezia—Erlotinib—lung cancer	0.0226	0.0336	CcSEcCtD
Bisacodyl—Colitis—Pemetrexed—lung cancer	0.0147	0.0219	CcSEcCtD
Bisacodyl—GPR55—G alpha (i) signalling events—GRM8—lung cancer	0.0121	0.0373	CbGpPWpGaD
Bisacodyl—Dehydration—Pemetrexed—lung cancer	0.0103	0.0154	CcSEcCtD
Bisacodyl—Dehydration—Gefitinib—lung cancer	0.0103	0.0153	CcSEcCtD
Bisacodyl—Anorectal discomfort—Etoposide—lung cancer	0.00987	0.0147	CcSEcCtD
Bisacodyl—Abdominal cramps—Irinotecan—lung cancer	0.00961	0.0143	CcSEcCtD
Bisacodyl—GPR55—G alpha (i) signalling events—GNG11—lung cancer	0.00935	0.0288	CbGpPWpGaD
Bisacodyl—Colitis—Topotecan—lung cancer	0.00883	0.0131	CcSEcCtD
Bisacodyl—Colitis—Erlotinib—lung cancer	0.00874	0.013	CcSEcCtD
Bisacodyl—GPR55—GPCR ligand binding—GIPR—lung cancer	0.00864	0.0266	CbGpPWpGaD
Bisacodyl—GPR55—G alpha (i) signalling events—ADCY1—lung cancer	0.00841	0.0259	CbGpPWpGaD
Bisacodyl—GPR55—Class A/1 (Rhodopsin-like receptors)—GRP—lung cancer	0.00795	0.0244	CbGpPWpGaD
Bisacodyl—GPR55—Class A/1 (Rhodopsin-like receptors)—OXTR—lung cancer	0.00795	0.0244	CbGpPWpGaD
Bisacodyl—GPR55—G alpha (i) signalling events—ANXA1—lung cancer	0.00735	0.0226	CbGpPWpGaD
Bisacodyl—GPR55—GPCR ligand binding—GRM8—lung cancer	0.00735	0.0226	CbGpPWpGaD
Bisacodyl—Malnutrition—Crizotinib—lung cancer	0.00733	0.0109	CcSEcCtD
Bisacodyl—GPR55—G alpha (i) signalling events—APP—lung cancer	0.00697	0.0214	CbGpPWpGaD
Bisacodyl—Haematochezia—Doxorubicin—lung cancer	0.00695	0.0103	CcSEcCtD
Bisacodyl—Malnutrition—Pemetrexed—lung cancer	0.0067	0.00996	CcSEcCtD
Bisacodyl—Malnutrition—Gefitinib—lung cancer	0.00666	0.0099	CcSEcCtD
Bisacodyl—Syncope—Crizotinib—lung cancer	0.00657	0.00978	CcSEcCtD
Bisacodyl—Loss of consciousness—Crizotinib—lung cancer	0.00644	0.00958	CcSEcCtD
Bisacodyl—Colitis—Irinotecan—lung cancer	0.00623	0.00927	CcSEcCtD
Bisacodyl—Dehydration—Erlotinib—lung cancer	0.00614	0.00914	CcSEcCtD
Bisacodyl—Angioedema—Gefitinib—lung cancer	0.00608	0.00905	CcSEcCtD
Bisacodyl—GPR55—GPCR ligand binding—OXTR—lung cancer	0.00605	0.0186	CbGpPWpGaD
Bisacodyl—GPR55—GPCR ligand binding—GRP—lung cancer	0.00605	0.0186	CbGpPWpGaD
Bisacodyl—Cramp muscle—Topotecan—lung cancer	0.00601	0.00895	CcSEcCtD
Bisacodyl—Syncope—Pemetrexed—lung cancer	0.00601	0.00894	CcSEcCtD
Bisacodyl—Loss of consciousness—Pemetrexed—lung cancer	0.00589	0.00876	CcSEcCtD
Bisacodyl—Shock—Crizotinib—lung cancer	0.00589	0.00876	CcSEcCtD
Bisacodyl—Nervous system disorder—Crizotinib—lung cancer	0.00587	0.00873	CcSEcCtD
Bisacodyl—GPR55—Class A/1 (Rhodopsin-like receptors)—ANXA1—lung cancer	0.00585	0.018	CbGpPWpGaD
Bisacodyl—GPR55—GPCR ligand binding—GNG11—lung cancer	0.00566	0.0174	CbGpPWpGaD
Bisacodyl—GPR55—Class A/1 (Rhodopsin-like receptors)—APP—lung cancer	0.00554	0.017	CbGpPWpGaD
Bisacodyl—Anaphylactic shock—Pemetrexed—lung cancer	0.00547	0.00813	CcSEcCtD
Bisacodyl—Shock—Pemetrexed—lung cancer	0.00538	0.008	CcSEcCtD
Bisacodyl—Nervous system disorder—Pemetrexed—lung cancer	0.00536	0.00798	CcSEcCtD
Bisacodyl—Shock—Gefitinib—lung cancer	0.00534	0.00795	CcSEcCtD
Bisacodyl—Nervous system disorder—Gefitinib—lung cancer	0.00533	0.00792	CcSEcCtD
Bisacodyl—Gastrointestinal disorder—Crizotinib—lung cancer	0.00516	0.00768	CcSEcCtD
Bisacodyl—Anorectal discomfort—Doxorubicin—lung cancer	0.00512	0.00762	CcSEcCtD
Bisacodyl—Colitis—Paclitaxel—lung cancer	0.00508	0.00756	CcSEcCtD
Bisacodyl—GPR55—GPCR downstream signaling—GIPR—lung cancer	0.00488	0.015	CbGpPWpGaD
Bisacodyl—GPR55—GPCR ligand binding—PTHLH—lung cancer	0.00473	0.0146	CbGpPWpGaD
Bisacodyl—Gastrointestinal disorder—Pemetrexed—lung cancer	0.00472	0.00702	CcSEcCtD
Bisacodyl—Gastrointestinal disorder—Gefitinib—lung cancer	0.00469	0.00698	CcSEcCtD
Bisacodyl—Gastrointestinal pain—Pemetrexed—lung cancer	0.00447	0.00665	CcSEcCtD
Bisacodyl—GPR55—GPCR ligand binding—ANXA1—lung cancer	0.00445	0.0137	CbGpPWpGaD
Bisacodyl—Gastrointestinal pain—Gefitinib—lung cancer	0.00444	0.00661	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—GIPR—lung cancer	0.00443	0.0136	CbGpPWpGaD
Bisacodyl—Dehydration—Irinotecan—lung cancer	0.00438	0.00652	CcSEcCtD
Bisacodyl—Abdominal pain—Pemetrexed—lung cancer	0.00432	0.00643	CcSEcCtD
Bisacodyl—GPR55—Class A/1 (Rhodopsin-like receptors)—AVP—lung cancer	0.00431	0.0132	CbGpPWpGaD
Bisacodyl—Colitis—Docetaxel—lung cancer	0.00431	0.00641	CcSEcCtD
Bisacodyl—Abdominal pain—Gefitinib—lung cancer	0.00429	0.00639	CcSEcCtD
Bisacodyl—Cramp muscle—Irinotecan—lung cancer	0.00424	0.00631	CcSEcCtD
Bisacodyl—GPR55—GPCR ligand binding—APP—lung cancer	0.00422	0.013	CbGpPWpGaD
Bisacodyl—Immune system disorder—Topotecan—lung cancer	0.00417	0.00621	CcSEcCtD
Bisacodyl—GPR55—GPCR downstream signaling—GRM8—lung cancer	0.00415	0.0128	CbGpPWpGaD
Bisacodyl—Diarrhoea—Crizotinib—lung cancer	0.00409	0.00609	CcSEcCtD
Bisacodyl—Hypersensitivity—Pemetrexed—lung cancer	0.00403	0.00599	CcSEcCtD
Bisacodyl—Malnutrition—Topotecan—lung cancer	0.00402	0.00598	CcSEcCtD
Bisacodyl—Hypersensitivity—Gefitinib—lung cancer	0.004	0.00595	CcSEcCtD
Bisacodyl—Malnutrition—Erlotinib—lung cancer	0.00398	0.00592	CcSEcCtD
Bisacodyl—Dehydration—Cisplatin—lung cancer	0.00398	0.00592	CcSEcCtD
Bisacodyl—Dizziness—Crizotinib—lung cancer	0.00396	0.00588	CcSEcCtD
Bisacodyl—Muscle spasms—Topotecan—lung cancer	0.00387	0.00575	CcSEcCtD
Bisacodyl—Cramp muscle—Cisplatin—lung cancer	0.00385	0.00573	CcSEcCtD
Bisacodyl—Vomiting—Crizotinib—lung cancer	0.0038	0.00566	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—GRM8—lung cancer	0.00377	0.0116	CbGpPWpGaD
Bisacodyl—Diarrhoea—Pemetrexed—lung cancer	0.00374	0.00556	CcSEcCtD
Bisacodyl—Diarrhoea—Gefitinib—lung cancer	0.00372	0.00553	CcSEcCtD
Bisacodyl—Angioedema—Topotecan—lung cancer	0.00367	0.00547	CcSEcCtD
Bisacodyl—Gastrointestinal pain—Teniposide—lung cancer	0.00362	0.00539	CcSEcCtD
Bisacodyl—Dizziness—Pemetrexed—lung cancer	0.00362	0.00538	CcSEcCtD
Bisacodyl—GPR55—G alpha (i) signalling events—POMC—lung cancer	0.0036	0.0111	CbGpPWpGaD
Bisacodyl—Dehydration—Paclitaxel—lung cancer	0.00357	0.00532	CcSEcCtD
Bisacodyl—Immune system disorder—Vinorelbine—lung cancer	0.00357	0.00531	CcSEcCtD
Bisacodyl—Syncope—Erlotinib—lung cancer	0.00357	0.00531	CcSEcCtD
Bisacodyl—Nausea—Crizotinib—lung cancer	0.00355	0.00529	CcSEcCtD
Bisacodyl—Abdominal discomfort—Cisplatin—lung cancer	0.00354	0.00527	CcSEcCtD
Bisacodyl—Cramp muscle—Etoposide—lung cancer	0.00353	0.00525	CcSEcCtD
Bisacodyl—Abdominal pain—Teniposide—lung cancer	0.0035	0.00521	CcSEcCtD
Bisacodyl—Loss of consciousness—Erlotinib—lung cancer	0.0035	0.0052	CcSEcCtD
Bisacodyl—Vomiting—Pemetrexed—lung cancer	0.00348	0.00517	CcSEcCtD
Bisacodyl—Cramp muscle—Paclitaxel—lung cancer	0.00346	0.00515	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—AXL—lung cancer	0.00346	0.0106	CbGpPWpGaD
Bisacodyl—Vomiting—Gefitinib—lung cancer	0.00345	0.00514	CcSEcCtD
Bisacodyl—Malnutrition—Vinorelbine—lung cancer	0.00344	0.00512	CcSEcCtD
Bisacodyl—GPR55—GPCR downstream signaling—OXTR—lung cancer	0.00342	0.0105	CbGpPWpGaD
Bisacodyl—GPR55—GPCR downstream signaling—GRP—lung cancer	0.00342	0.0105	CbGpPWpGaD
Bisacodyl—Anaphylactic shock—Topotecan—lung cancer	0.00328	0.00488	CcSEcCtD
Bisacodyl—GPR55—GPCR ligand binding—AVP—lung cancer	0.00328	0.0101	CbGpPWpGaD
Bisacodyl—Hypersensitivity—Teniposide—lung cancer	0.00326	0.00485	CcSEcCtD
Bisacodyl—Nausea—Pemetrexed—lung cancer	0.00325	0.00483	CcSEcCtD
Bisacodyl—Nausea—Gefitinib—lung cancer	0.00323	0.0048	CcSEcCtD
Bisacodyl—Nervous system disorder—Topotecan—lung cancer	0.00322	0.00479	CcSEcCtD
Bisacodyl—GPR55—GPCR downstream signaling—GNG11—lung cancer	0.0032	0.00984	CbGpPWpGaD
Bisacodyl—Shock—Erlotinib—lung cancer	0.00319	0.00475	CcSEcCtD
Bisacodyl—Nervous system disorder—Erlotinib—lung cancer	0.00318	0.00474	CcSEcCtD
Bisacodyl—Angioedema—Vinorelbine—lung cancer	0.00314	0.00468	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—GRP—lung cancer	0.0031	0.00954	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—OXTR—lung cancer	0.0031	0.00954	CbGpPWpGaD
Bisacodyl—Diarrhoea—Teniposide—lung cancer	0.00303	0.00451	CcSEcCtD
Bisacodyl—Dehydration—Docetaxel—lung cancer	0.00303	0.00451	CcSEcCtD
Bisacodyl—Immune system disorder—Irinotecan—lung cancer	0.00294	0.00438	CcSEcCtD
Bisacodyl—Cramp muscle—Docetaxel—lung cancer	0.00293	0.00436	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—GNG11—lung cancer	0.00291	0.00893	CbGpPWpGaD
Bisacodyl—GPR55—GPCR downstream signaling—ADCY1—lung cancer	0.00288	0.00885	CbGpPWpGaD
Bisacodyl—Immune system disorder—Gemcitabine—lung cancer	0.00287	0.00427	CcSEcCtD
Bisacodyl—GPR55—Class A/1 (Rhodopsin-like receptors)—POMC—lung cancer	0.00286	0.0088	CbGpPWpGaD
Bisacodyl—Gastrointestinal disorder—Topotecan—lung cancer	0.00283	0.00422	CcSEcCtD
Bisacodyl—Vomiting—Teniposide—lung cancer	0.00282	0.00419	CcSEcCtD
Bisacodyl—Anaphylactic shock—Vinorelbine—lung cancer	0.00281	0.00418	CcSEcCtD
Bisacodyl—Gastrointestinal disorder—Erlotinib—lung cancer	0.0028	0.00417	CcSEcCtD
Bisacodyl—GPR55—G alpha (i) signalling events—CXCL8—lung cancer	0.00279	0.00856	CbGpPWpGaD
Bisacodyl—Headache—Teniposide—lung cancer	0.00277	0.00413	CcSEcCtD
Bisacodyl—Gastrointestinal pain—Vinblastine—lung cancer	0.00276	0.00411	CcSEcCtD
Bisacodyl—Nervous system disorder—Vinorelbine—lung cancer	0.00275	0.0041	CcSEcCtD
Bisacodyl—Muscle spasms—Irinotecan—lung cancer	0.00273	0.00406	CcSEcCtD
Bisacodyl—Colitis—Doxorubicin—lung cancer	0.00269	0.004	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—COL4A2—lung cancer	0.00269	0.00826	CbGpPWpGaD
Bisacodyl—Gastrointestinal pain—Topotecan—lung cancer	0.00268	0.00399	CcSEcCtD
Bisacodyl—GPR55—GPCR downstream signaling—PTHLH—lung cancer	0.00268	0.00822	CbGpPWpGaD
Bisacodyl—Immune system disorder—Cisplatin—lung cancer	0.00267	0.00398	CcSEcCtD
Bisacodyl—Abdominal pain—Vinblastine—lung cancer	0.00267	0.00397	CcSEcCtD
Bisacodyl—Gastrointestinal pain—Erlotinib—lung cancer	0.00266	0.00395	CcSEcCtD
Bisacodyl—Nausea—Teniposide—lung cancer	0.00263	0.00391	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—GIPR—lung cancer	0.00262	0.00805	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—ADCY1—lung cancer	0.00261	0.00803	CbGpPWpGaD
Bisacodyl—Abdominal pain—Topotecan—lung cancer	0.00259	0.00386	CcSEcCtD
Bisacodyl—Malnutrition—Cisplatin—lung cancer	0.00258	0.00383	CcSEcCtD
Bisacodyl—Abdominal pain—Erlotinib—lung cancer	0.00257	0.00382	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—PPP2R1B—lung cancer	0.00255	0.00783	CbGpPWpGaD
Bisacodyl—Syncope—Irinotecan—lung cancer	0.00254	0.00379	CcSEcCtD
Bisacodyl—GPR55—GPCR downstream signaling—ANXA1—lung cancer	0.00252	0.00773	CbGpPWpGaD
Bisacodyl—Loss of consciousness—Irinotecan—lung cancer	0.00249	0.00371	CcSEcCtD
Bisacodyl—Hypersensitivity—Vinblastine—lung cancer	0.00249	0.0037	CcSEcCtD
Bisacodyl—Muscle spasms—Cisplatin—lung cancer	0.00248	0.00368	CcSEcCtD
Bisacodyl—Immune system disorder—Etoposide—lung cancer	0.00245	0.00364	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—SDC4—lung cancer	0.00245	0.00752	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—PTHLH—lung cancer	0.00243	0.00747	CbGpPWpGaD
Bisacodyl—Gastrointestinal disorder—Vinorelbine—lung cancer	0.00242	0.00361	CcSEcCtD
Bisacodyl—Hypersensitivity—Topotecan—lung cancer	0.00242	0.0036	CcSEcCtD
Bisacodyl—Immune system disorder—Paclitaxel—lung cancer	0.0024	0.00357	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—DUSP3—lung cancer	0.0024	0.00736	CbGpPWpGaD
Bisacodyl—GPR55—GPCR downstream signaling—APP—lung cancer	0.00238	0.00733	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—RHEB—lung cancer	0.00235	0.00722	CbGpPWpGaD
Bisacodyl—Anaphylactic shock—Irinotecan—lung cancer	0.00232	0.00344	CcSEcCtD
Bisacodyl—Malnutrition—Paclitaxel—lung cancer	0.00231	0.00344	CcSEcCtD
Bisacodyl—Diarrhoea—Vinblastine—lung cancer	0.00231	0.00344	CcSEcCtD
Bisacodyl—Gastrointestinal pain—Vinorelbine—lung cancer	0.0023	0.00342	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—ANXA1—lung cancer	0.00228	0.00702	CbGpPWpGaD
Bisacodyl—Shock—Irinotecan—lung cancer	0.00228	0.00339	CcSEcCtD
Bisacodyl—Nervous system disorder—Irinotecan—lung cancer	0.00227	0.00338	CcSEcCtD
Bisacodyl—Muscle spasms—Etoposide—lung cancer	0.00227	0.00338	CcSEcCtD
Bisacodyl—Anaphylactic shock—Gemcitabine—lung cancer	0.00226	0.00336	CcSEcCtD
Bisacodyl—Diarrhoea—Topotecan—lung cancer	0.00225	0.00334	CcSEcCtD
Bisacodyl—Dizziness—Vinblastine—lung cancer	0.00223	0.00332	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—GRM8—lung cancer	0.00223	0.00685	CbGpPWpGaD
Bisacodyl—Muscle spasms—Paclitaxel—lung cancer	0.00222	0.00331	CcSEcCtD
Bisacodyl—Diarrhoea—Erlotinib—lung cancer	0.00222	0.00331	CcSEcCtD
Bisacodyl—Abdominal pain—Vinorelbine—lung cancer	0.00222	0.0033	CcSEcCtD
Bisacodyl—GPR55—Class A/1 (Rhodopsin-like receptors)—CXCL8—lung cancer	0.00222	0.00681	CbGpPWpGaD
Bisacodyl—Nervous system disorder—Gemcitabine—lung cancer	0.00221	0.00329	CcSEcCtD
Bisacodyl—GPR55—GPCR ligand binding—POMC—lung cancer	0.00218	0.0067	CbGpPWpGaD
Bisacodyl—Dizziness—Topotecan—lung cancer	0.00217	0.00323	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—APP—lung cancer	0.00217	0.00666	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—SKI—lung cancer	0.00216	0.00663	CbGpPWpGaD
Bisacodyl—Vomiting—Vinblastine—lung cancer	0.00215	0.0032	CcSEcCtD
Bisacodyl—Dizziness—Erlotinib—lung cancer	0.00215	0.00319	CcSEcCtD
Bisacodyl—Headache—Vinblastine—lung cancer	0.00212	0.00315	CcSEcCtD
Bisacodyl—Angioedema—Paclitaxel—lung cancer	0.00211	0.00315	CcSEcCtD
Bisacodyl—Anaphylactic shock—Cisplatin—lung cancer	0.0021	0.00313	CcSEcCtD
Bisacodyl—Vomiting—Topotecan—lung cancer	0.00209	0.0031	CcSEcCtD
Bisacodyl—Syncope—Paclitaxel—lung cancer	0.00208	0.00309	CcSEcCtD
Bisacodyl—Loss of consciousness—Etoposide—lung cancer	0.00207	0.00309	CcSEcCtD
Bisacodyl—Hypersensitivity—Vinorelbine—lung cancer	0.00207	0.00308	CcSEcCtD
Bisacodyl—Vomiting—Erlotinib—lung cancer	0.00206	0.00307	CcSEcCtD
Bisacodyl—Nervous system disorder—Cisplatin—lung cancer	0.00206	0.00307	CcSEcCtD
Bisacodyl—Headache—Topotecan—lung cancer	0.00206	0.00306	CcSEcCtD
Bisacodyl—Immune system disorder—Docetaxel—lung cancer	0.00204	0.00303	CcSEcCtD
Bisacodyl—Headache—Erlotinib—lung cancer	0.00203	0.00303	CcSEcCtD
Bisacodyl—Loss of consciousness—Paclitaxel—lung cancer	0.00203	0.00303	CcSEcCtD
Bisacodyl—Nausea—Vinblastine—lung cancer	0.00201	0.00299	CcSEcCtD
Bisacodyl—Gastrointestinal disorder—Irinotecan—lung cancer	0.002	0.00297	CcSEcCtD
Bisacodyl—Malnutrition—Docetaxel—lung cancer	0.00196	0.00292	CcSEcCtD
Bisacodyl—Nausea—Topotecan—lung cancer	0.00195	0.0029	CcSEcCtD
Bisacodyl—Gastrointestinal disorder—Gemcitabine—lung cancer	0.00195	0.0029	CcSEcCtD
Bisacodyl—Abdominal discomfort—Methotrexate—lung cancer	0.00194	0.00289	CcSEcCtD
Bisacodyl—Nausea—Erlotinib—lung cancer	0.00193	0.00287	CcSEcCtD
Bisacodyl—Anaphylactic shock—Etoposide—lung cancer	0.00193	0.00287	CcSEcCtD
Bisacodyl—Diarrhoea—Vinorelbine—lung cancer	0.00192	0.00286	CcSEcCtD
Bisacodyl—Gastrointestinal pain—Irinotecan—lung cancer	0.00189	0.00282	CcSEcCtD
Bisacodyl—Dehydration—Doxorubicin—lung cancer	0.00189	0.00281	CcSEcCtD
Bisacodyl—Anaphylactic shock—Paclitaxel—lung cancer	0.00189	0.00281	CcSEcCtD
Bisacodyl—Muscle spasms—Docetaxel—lung cancer	0.00189	0.00281	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—PXN—lung cancer	0.00187	0.00576	CbGpPWpGaD
Bisacodyl—Shock—Paclitaxel—lung cancer	0.00186	0.00276	CcSEcCtD
Bisacodyl—Dizziness—Vinorelbine—lung cancer	0.00186	0.00276	CcSEcCtD
Bisacodyl—GPR55—GPCR downstream signaling—AVP—lung cancer	0.00185	0.0057	CbGpPWpGaD
Bisacodyl—Nervous system disorder—Paclitaxel—lung cancer	0.00185	0.00276	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—GRP—lung cancer	0.00183	0.00564	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—OXTR—lung cancer	0.00183	0.00564	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—AKR1C1—lung cancer	0.00183	0.00564	CbGpPWpGaD
Bisacodyl—Abdominal pain—Irinotecan—lung cancer	0.00183	0.00272	CcSEcCtD
Bisacodyl—Gastrointestinal disorder—Cisplatin—lung cancer	0.00182	0.0027	CcSEcCtD
Bisacodyl—Vomiting—Vinorelbine—lung cancer	0.00179	0.00266	CcSEcCtD
Bisacodyl—Headache—Vinorelbine—lung cancer	0.00176	0.00262	CcSEcCtD
Bisacodyl—Syncope—Docetaxel—lung cancer	0.00176	0.00262	CcSEcCtD
Bisacodyl—Loss of consciousness—Docetaxel—lung cancer	0.00172	0.00256	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—GNG11—lung cancer	0.00172	0.00528	CbGpPWpGaD
Bisacodyl—Hypersensitivity—Irinotecan—lung cancer	0.00171	0.00254	CcSEcCtD
Bisacodyl—GPR55—GPCR ligand binding—CXCL8—lung cancer	0.00169	0.00519	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—AVP—lung cancer	0.00168	0.00518	CbGpPWpGaD
Bisacodyl—Nausea—Vinorelbine—lung cancer	0.00167	0.00248	CcSEcCtD
Bisacodyl—Gastrointestinal disorder—Etoposide—lung cancer	0.00166	0.00247	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—VEGFC—lung cancer	0.00163	0.00502	CbGpPWpGaD
Bisacodyl—Gastrointestinal disorder—Paclitaxel—lung cancer	0.00163	0.00243	CcSEcCtD
Bisacodyl—Anaphylactic shock—Docetaxel—lung cancer	0.0016	0.00238	CcSEcCtD
Bisacodyl—Diarrhoea—Irinotecan—lung cancer	0.00158	0.00236	CcSEcCtD
Bisacodyl—Gastrointestinal pain—Etoposide—lung cancer	0.00157	0.00234	CcSEcCtD
Bisacodyl—Shock—Docetaxel—lung cancer	0.00157	0.00234	CcSEcCtD
Bisacodyl—Nervous system disorder—Docetaxel—lung cancer	0.00157	0.00234	CcSEcCtD
Bisacodyl—Hypersensitivity—Cisplatin—lung cancer	0.00155	0.0023	CcSEcCtD
Bisacodyl—Gastrointestinal pain—Paclitaxel—lung cancer	0.00154	0.0023	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—ADCY1—lung cancer	0.00154	0.00475	CbGpPWpGaD
Bisacodyl—Diarrhoea—Gemcitabine—lung cancer	0.00154	0.0023	CcSEcCtD
Bisacodyl—Dizziness—Irinotecan—lung cancer	0.00153	0.00228	CcSEcCtD
Bisacodyl—Abdominal pain—Etoposide—lung cancer	0.00152	0.00227	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—PPP2R1B—lung cancer	0.0015	0.00462	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—SMARCA4—lung cancer	0.0015	0.00462	CbGpPWpGaD
Bisacodyl—Abdominal pain—Paclitaxel—lung cancer	0.00149	0.00222	CcSEcCtD
Bisacodyl—Vomiting—Irinotecan—lung cancer	0.00147	0.00219	CcSEcCtD
Bisacodyl—Immune system disorder—Methotrexate—lung cancer	0.00147	0.00218	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—HSPB1—lung cancer	0.00145	0.00446	CbGpPWpGaD
Bisacodyl—Headache—Irinotecan—lung cancer	0.00145	0.00216	CcSEcCtD
Bisacodyl—Diarrhoea—Cisplatin—lung cancer	0.00144	0.00214	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—PTHLH—lung cancer	0.00144	0.00441	CbGpPWpGaD
Bisacodyl—Vomiting—Gemcitabine—lung cancer	0.00143	0.00213	CcSEcCtD
Bisacodyl—Hypersensitivity—Etoposide—lung cancer	0.00142	0.00211	CcSEcCtD
Bisacodyl—Malnutrition—Methotrexate—lung cancer	0.00141	0.0021	CcSEcCtD
Bisacodyl—Headache—Gemcitabine—lung cancer	0.00141	0.0021	CcSEcCtD
Bisacodyl—Hypersensitivity—Paclitaxel—lung cancer	0.00139	0.00207	CcSEcCtD
Bisacodyl—Gastrointestinal disorder—Docetaxel—lung cancer	0.00138	0.00206	CcSEcCtD
Bisacodyl—Nausea—Irinotecan—lung cancer	0.00138	0.00205	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—ANXA1—lung cancer	0.00135	0.00415	CbGpPWpGaD
Bisacodyl—Nausea—Gemcitabine—lung cancer	0.00134	0.00199	CcSEcCtD
Bisacodyl—Vomiting—Cisplatin—lung cancer	0.00134	0.00199	CcSEcCtD
Bisacodyl—Diarrhoea—Etoposide—lung cancer	0.00132	0.00196	CcSEcCtD
Bisacodyl—Carbinoxamine—CYP2E1—lung cancer	0.00131	0.536	CrCbGaD
Bisacodyl—Gastrointestinal pain—Docetaxel—lung cancer	0.00131	0.00195	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—FLT1—lung cancer	0.00131	0.00402	CbGpPWpGaD
Bisacodyl—GPR55—GPCR downstream signaling—PIK3CG—lung cancer	0.00129	0.00398	CbGpPWpGaD
Bisacodyl—Diarrhoea—Paclitaxel—lung cancer	0.00129	0.00192	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—NOTCH3—lung cancer	0.00128	0.00393	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—APP—lung cancer	0.00128	0.00393	CbGpPWpGaD
Bisacodyl—Dizziness—Etoposide—lung cancer	0.00127	0.00189	CcSEcCtD
Bisacodyl—Immune system disorder—Doxorubicin—lung cancer	0.00127	0.00189	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—FGF9—lung cancer	0.00127	0.0039	CbGpPWpGaD
Bisacodyl—Abdominal pain—Docetaxel—lung cancer	0.00127	0.00188	CcSEcCtD
Bisacodyl—Dizziness—Paclitaxel—lung cancer	0.00125	0.00186	CcSEcCtD
Bisacodyl—Nausea—Cisplatin—lung cancer	0.00125	0.00186	CcSEcCtD
Bisacodyl—GPR55—GPCR downstream signaling—POMC—lung cancer	0.00123	0.00379	CbGpPWpGaD
Bisacodyl—Vomiting—Etoposide—lung cancer	0.00122	0.00182	CcSEcCtD
Bisacodyl—Malnutrition—Doxorubicin—lung cancer	0.00122	0.00182	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—JUNB—lung cancer	0.00121	0.00372	CbGpPWpGaD
Bisacodyl—Headache—Etoposide—lung cancer	0.00121	0.0018	CcSEcCtD
Bisacodyl—Vomiting—Paclitaxel—lung cancer	0.0012	0.00179	CcSEcCtD
Bisacodyl—Headache—Paclitaxel—lung cancer	0.00118	0.00176	CcSEcCtD
Bisacodyl—Hypersensitivity—Docetaxel—lung cancer	0.00118	0.00175	CcSEcCtD
Bisacodyl—Muscle spasms—Doxorubicin—lung cancer	0.00118	0.00175	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—PIK3CG—lung cancer	0.00118	0.00361	CbGpPWpGaD
Bisacodyl—Anaphylactic shock—Methotrexate—lung cancer	0.00115	0.00172	CcSEcCtD
Bisacodyl—Nausea—Etoposide—lung cancer	0.00114	0.0017	CcSEcCtD
Bisacodyl—GPR55—GPCR downstream signaling—PIK3CD—lung cancer	0.00114	0.0035	CbGpPWpGaD
Bisacodyl—Brompheniramine—CYP2E1—lung cancer	0.00113	0.464	CrCbGaD
Bisacodyl—Nervous system disorder—Methotrexate—lung cancer	0.00113	0.00168	CcSEcCtD
Bisacodyl—Nausea—Paclitaxel—lung cancer	0.00112	0.00167	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—POMC—lung cancer	0.00112	0.00344	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—STK11—lung cancer	0.0011	0.00338	CbGpPWpGaD
Bisacodyl—Syncope—Doxorubicin—lung cancer	0.0011	0.00163	CcSEcCtD
Bisacodyl—Diarrhoea—Docetaxel—lung cancer	0.0011	0.00163	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—IL6R—lung cancer	0.00109	0.00336	CbGpPWpGaD
Bisacodyl—Loss of consciousness—Doxorubicin—lung cancer	0.00108	0.0016	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—FOXO3—lung cancer	0.00106	0.00326	CbGpPWpGaD
Bisacodyl—Dizziness—Docetaxel—lung cancer	0.00106	0.00157	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—MAP2K1—lung cancer	0.00104	0.0032	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—PIK3CD—lung cancer	0.00103	0.00318	CbGpPWpGaD
Bisacodyl—Vomiting—Docetaxel—lung cancer	0.00102	0.00151	CcSEcCtD
Bisacodyl—Headache—Docetaxel—lung cancer	0.001	0.00149	CcSEcCtD
Bisacodyl—Anaphylactic shock—Doxorubicin—lung cancer	0.000999	0.00149	CcSEcCtD
Bisacodyl—Gastrointestinal disorder—Methotrexate—lung cancer	0.000996	0.00148	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—AVP—lung cancer	0.000995	0.00306	CbGpPWpGaD
Bisacodyl—GPR55—GPCR downstream signaling—PIK3CB—lung cancer	0.000992	0.00305	CbGpPWpGaD
Bisacodyl—Shock—Doxorubicin—lung cancer	0.000983	0.00146	CcSEcCtD
Bisacodyl—Nervous system disorder—Doxorubicin—lung cancer	0.00098	0.00146	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—IGF1R—lung cancer	0.000958	0.00294	CbGpPWpGaD
Bisacodyl—GPR55—GPCR downstream signaling—CXCL8—lung cancer	0.000953	0.00293	CbGpPWpGaD
Bisacodyl—Nausea—Docetaxel—lung cancer	0.000951	0.00141	CcSEcCtD
Bisacodyl—Gastrointestinal pain—Methotrexate—lung cancer	0.000943	0.0014	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—HES1—lung cancer	0.000941	0.00289	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—RAF1—lung cancer	0.000923	0.00284	CbGpPWpGaD
Bisacodyl—Abdominal pain—Methotrexate—lung cancer	0.000912	0.00136	CcSEcCtD
Bisacodyl—GPR55—GPCR downstream signaling—IL2—lung cancer	0.000911	0.0028	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—PIK3CB—lung cancer	0.000901	0.00277	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—CXCL8—lung cancer	0.000866	0.00266	CbGpPWpGaD
Bisacodyl—Gastrointestinal disorder—Doxorubicin—lung cancer	0.000862	0.00128	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—ERBB3—lung cancer	0.00086	0.00264	CbGpPWpGaD
Bisacodyl—Hypersensitivity—Methotrexate—lung cancer	0.00085	0.00126	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—IL2—lung cancer	0.000827	0.00254	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—TERT—lung cancer	0.000824	0.00253	CbGpPWpGaD
Bisacodyl—Gastrointestinal pain—Doxorubicin—lung cancer	0.000817	0.00122	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—FGFR1—lung cancer	0.0008	0.00246	CbGpPWpGaD
Bisacodyl—Abdominal pain—Doxorubicin—lung cancer	0.00079	0.00117	CcSEcCtD
Bisacodyl—Diarrhoea—Methotrexate—lung cancer	0.000789	0.00117	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—HIF1A—lung cancer	0.000788	0.00242	CbGpPWpGaD
Bisacodyl—Dizziness—Methotrexate—lung cancer	0.000763	0.00113	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—APOA1—lung cancer	0.000761	0.00234	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—KDR—lung cancer	0.000754	0.00232	CbGpPWpGaD
Bisacodyl—Hypersensitivity—Doxorubicin—lung cancer	0.000736	0.00109	CcSEcCtD
Bisacodyl—Vomiting—Methotrexate—lung cancer	0.000734	0.00109	CcSEcCtD
Bisacodyl—Headache—Methotrexate—lung cancer	0.000723	0.00108	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—PIK3CG—lung cancer	0.000695	0.00213	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—KIT—lung cancer	0.000695	0.00213	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—APC—lung cancer	0.000695	0.00213	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—NRAS—lung cancer	0.000695	0.00213	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—EGF—lung cancer	0.000687	0.00211	CbGpPWpGaD
Bisacodyl—Nausea—Methotrexate—lung cancer	0.000685	0.00102	CcSEcCtD
Bisacodyl—Diarrhoea—Doxorubicin—lung cancer	0.000684	0.00102	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—MAPK3—lung cancer	0.000665	0.00204	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—POMC—lung cancer	0.000661	0.00203	CbGpPWpGaD
Bisacodyl—Dizziness—Doxorubicin—lung cancer	0.000661	0.000983	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—BRAF—lung cancer	0.000653	0.00201	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—IL6R—lung cancer	0.000645	0.00198	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—CREBBP—lung cancer	0.000644	0.00198	CbGpPWpGaD
Bisacodyl—Vomiting—Doxorubicin—lung cancer	0.000635	0.000945	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—EGFR—lung cancer	0.000633	0.00194	CbGpPWpGaD
Bisacodyl—Headache—Doxorubicin—lung cancer	0.000626	0.000931	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—MAP2K1—lung cancer	0.000615	0.00189	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—PIK3CD—lung cancer	0.000611	0.00188	CbGpPWpGaD
Bisacodyl—GPR55—GPCR downstream signaling—PIK3CA—lung cancer	0.000605	0.00186	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—KRAS—lung cancer	0.000598	0.00184	CbGpPWpGaD
Bisacodyl—Nausea—Doxorubicin—lung cancer	0.000593	0.000883	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—PIK3CA—lung cancer	0.000549	0.00169	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—MDM2—lung cancer	0.000547	0.00168	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—RAF1—lung cancer	0.000545	0.00168	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—ERBB2—lung cancer	0.000539	0.00166	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—PIK3CB—lung cancer	0.000532	0.00164	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—MTOR—lung cancer	0.000532	0.00164	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—CXCL8—lung cancer	0.000511	0.00157	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—HRAS—lung cancer	0.000508	0.00156	CbGpPWpGaD
Bisacodyl—GPR55—GPCR downstream signaling—AKT1—lung cancer	0.000494	0.00152	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—CASP3—lung cancer	0.000489	0.0015	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—IL2—lung cancer	0.000489	0.0015	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—IL6—lung cancer	0.000486	0.00149	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—CCND1—lung cancer	0.000476	0.00146	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—JUN—lung cancer	0.000475	0.00146	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—MMP9—lung cancer	0.000463	0.00142	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—CDKN1A—lung cancer	0.000461	0.00142	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—PTEN—lung cancer	0.00046	0.00141	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—AKT1—lung cancer	0.000449	0.00138	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—EP300—lung cancer	0.000439	0.00135	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—SRC—lung cancer	0.000426	0.00131	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—VEGFA—lung cancer	0.000415	0.00128	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—STAT3—lung cancer	0.000411	0.00126	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—NRAS—lung cancer	0.00041	0.00126	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—MAPK3—lung cancer	0.000393	0.00121	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—MYC—lung cancer	0.000382	0.00117	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—EGFR—lung cancer	0.000374	0.00115	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—KRAS—lung cancer	0.000353	0.00109	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—PIK3CA—lung cancer	0.000324	0.000997	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—TP53—lung cancer	0.000314	0.000965	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—HRAS—lung cancer	0.0003	0.000923	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—IL6—lung cancer	0.000287	0.000883	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—AKT1—lung cancer	0.000265	0.000815	CbGpPWpGaD
